AzTrials
AzTrials

Diabetes (DM)NUTPOOLNCT07205978

Nut Consumption and Prevention of Non-communicable Diseases: A Global Individual Participant Data Meta-analysis

An observational study of Diabetes (DM) and Cardio Vascular Disease, run by Institut Investigacio Sanitaria Pere Virgili at 2 sites in 2 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The relationship between nut consumption and the risk of developing non-communicable diseases (NCDs) has been a subject of growing interest. However, the findings from previous studies have been conflicting for some health outcomes, such as type-2 diabetes, and have been underexplored for other outcomes, such as… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Diabetes (DM), Cardio Vascular Disease, Cancer
How many people
1,000,000 participants
Where
2 sitesin 2 countries
Study dates
1 Oct 2025to 30 Jan 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Adult participants from Cohorts larger than 5000 participants and with at least a mean of 5 years of follow-up

Who may be able to join

  • Prospective studies with:
  • Dietary data (consumption of nuts, both overall and/or by type) from semiquantitative food frequency questionnaires
  • Available data on at least two of the health outcomes of interest
  • More than 1,000 adult participants (aged 18 and over)
  • A minimum of five years of median follow-up

Who cannot join

  • Prospective studies determining the consumption of nuts in combination with other food groups (e.g., seeds) or with other nut forms (e.g., butter or oil)
  • Participants with:
  • Missing data on age, sex, and nut consumption.
  • Extreme energy intakes (<600 or >3,500 kcal for women and <800 or >4,200 kcal for men)
  • The disease of interest at baseline

Trial locations and contacts

2 sites in 2 countries.

2 sites in 2 countries

Denmark1 site
  • Department of Public Health, Section of Epidemiology

    Copenhagen

Other trials in Denmark

Spain1 site
  • Human Nutrition Unit - Alimentació, Nutrició, Desenvolupament i Salut Mental (ANUT-DSM).

    Reus, Catalonia, 43201

Other trials in Spain

About this study

The relationship between nut consumption and the risk of developing non-communicable diseases (NCDs) has been a subject of growing interest. However, the findings from previous studies have been conflicting for some health outcomes, such as type-2 diabetes, and have been underexplored for other outcomes, such as neurodegenerative diseases. One contributing factor to these inconsistencies lies in the different analytical approaches and confounding factors used across studies. Furthermore, the majority of previous studies have primarily focused on populations in Europe or the United States, potentially limiting the generalizability of the findings to other global regions. The NUTPOOL project aims to address these gaps by conducting an extensive individual participant data (IPD) meta-analysis. This study will evaluate the association between total and specific types of nut consumption and the future risk of NCDs.

Read the detailed description

NCDs account for 74% of global deaths, with 41% of these occurring prematurely in individuals aged 70 years and older. Type 2 diabetes, cardiovascular diseases (CVD), and cancer are among the major chronic diseases that affect people across countries and contribute to premature deaths. Notably, 77% of all NCD deaths and 86% of premature deaths occur in low- and middle-income countries. Reducing premature mortality from NCDs through preventive strategies, especially in low- and middle-income countries, was identified as a target in the Sustainable Development Goals from the World Health Organization. Additionally, as populations age, dementia is gaining recognition as a major public health concern. Dementia is among the leading causes of death and disability, with significant economic implications. Therefore, implementing preventive strategies to maintain cognitive function and delay cognitive decline is essential.

Adhering to a healthy diet is an effective and cost-efficient strategy to reduce NCDs. In fact, unhealthy diets have been linked to over 30% of NCDs and cognitive decline. Nuts are a common food component of several plant-based diets that have shown beneficial effects in preventing NCDs. Nuts are a diverse food group comprising a wide variety of oily kernels with a unique nutritional profile, including high amounts of protein, fiber, unsaturated fatty acids, vitamins, polyphenols, and other phytochemicals. These nutrients may contribute to their beneficial effects, such as antioxidant, anti-inflammatory, antihypertensive, anti-lipidemic, and anti-aging properties, as well as their potential positive influence on gut microbiota modulation.

Prior research has examined the impact of nuts on various health outcomes; however, many of these studies have focused on intermediate outcomes, obtained controversial results, and have been conducted primarily in European countries or the United States. Furthermore, the data has been analyzed using a variety of approaches, the studies were designed in different ways, and different covariates were added to the statistical models, potentially leading to inconsistencies and compromising the reliability of the comparison between studies. These inconsistencies emphasize the need for further research to elucidate the role of total nuts and specific types of nut consumption on the development of highly prevalent NCDs, as well as to allow the generalizability of the results across different countries and ethnicities.

In the NUTPOOL project, the objective is to address these knowledge gaps and provide a thorough assessment of the associations between total nuts and specific types of nuts in relation to a wide range of NCDs and mortality. The results from this global collaborative project will be representative of the worldwide populations, as they include prospective cohort studies from different countries, including not only American and European countries, but also Asian and Oceania. Additionally, the focus is on total and specific types of nuts, along with highly prevalent and relevant outcomes such as type 2 diabetes, cardiovascular disease (CVD), cancer, dementia, and mortality. To ensure consistency and reliability, the analyses will be standardized using Individual Participant Data (IPD) meta-analyses.

The selection of studies will be conducted after the identification of cohorts with data available on nut consumption. This identification process will be based on information comprehensively extracted from recently published systematic reviews and meta-analysis (SRMAs) on the subject, as well as through extensive research network. Invitations will be extended to as many eligible cohorts as possible to mitigate selection bias and ensure comprehensive participation in the study. Studies will be eligible for inclusion if they reported reliable nutrition data from a food frequency questionnaire (FFQ) regarding total nuts and/or specific nuts, along with well-defined data on at least two of the health outcomes. The study population had to be at least 1,000 adults, and the study had to span a minimum of five years or more of median follow-up, enabling time-dependent analyses.

The assessment of nut consumption involves standardizing the amount consumed to a standard serving size (1 serving = 28 g or 1 oz.). The cumulative average or baseline nut consumption will be used according to the data collection methods employed for each cohort. Nut consumption will be analyzed as both a continuous and a categorical variable. The methods used to ascertain high-prevalence NCDs include medical diagnosis, official national or regional death registers, self-reported cases, and medication checks.

The statistical analysis plan will entail the subsequent two steps: First, each cohort will follow a standardized and harmonized protocol to analyze the data. Secondly, centralized meta-analyses will be performed. Multivariable Cox proportional hazards models will be used to estimate the risk of NCDs. Separate models will be conducted for categories of total nuts and specific types of nuts. A dose-response analysis will also be conducted. The models will include different levels of adjustment:

  • Model 1: age and sex
  • Model 2: M1 + race, family history of NCDs of interest, personal history of hypercholesterolemia, education level, physical activity, alcohol consumption, smoking, total energy intake, cohort specific adjustements (e.g. allocation to intervention group for intervention cohorts; recruitment centre for multi-centre cohorts; socio-economic status and urban/rural residence, as deemed appropriate)
  • Model 3: M2 + red and processed meat, fruit and vegetable, potatoes, fish, legume, egg, cereal, whole grain, coffee, tea, sugar- and artificially-sweetened beverages and cooking fats. For analysis by subtype of nuts, model 2 will also be mutually adjusted for each other types of nut.
  • Model 4: M3 + body mass index Subgroups analyses will be performed based on age, sex, race, educational level, physical activity level, smoking status, body weight status, hypercholesterolemia and diabetes status at baseline.

All analyses will be restricted to participants with complete data on age, sex, nut consumption, or the disease of interest. The missing data will be handled as follows: a) If there is more than 20% missing data for a covariate, the variable will not be included in the adjustment models; b) If there is 20% or less missing data, for continuous variables, the media should be imputed, and for categorical variables, an additional missing category should be created and used it in the models to avoid losing count or power.

Once all the cohorts have provided the summary statistics, and the results have been verified and harmonized, they will be combined by inverse-variance weighted random effects meta-analyses (DerSimonian and Laird procedure). The between-study variance will be used to assess heterogeneity. To ensure the reliability of the results, additional meta-analyses will be conducted by systematically excluding one cohort at a time. Statistical meta-analyses will be performed using Stata/SE software, version 18.0 (StataCorp, College Station, TX).

Keywords
nuts, moratlity, cardiovascular disease, Diabetes, dementia, IPD, epidemiology, Tree nuts, Peanuts, walnuts, almonds, pistachios, macadamia, cashewnut, pine nuts, Brazil nuts, Adult, Type-2 diabetes, Diabetes Mellitus, type 1*, Cardiovascular diseases*, Coronary health disesase
Medical subject headings
Diabetes Mellitus, Neoplasms, Dementia, Alzheimer Disease, Parkinson Disease, Death, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07205978
Study groupRoleWhat they receive
The proposed aims will be evaluated using data from prospective cohort studies from around the worldProspective studies will be eligible if they have good quality nutrition data from a food frequency questionnaire (FFQ) about total nuts and/or specific nuts, and well-ascertained data of at least two of the health outcomes (T2D, CVD, cancer, or dementia), more than 1,000 adult participants, and accrued five years or more of median follow-up that allows time-dependent analyses. We expect 25-30 cohorts to be included in the final analysis.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Type-2 diabetes incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  2. CVD incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  3. Coronary health disesase incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  4. Stroke incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  5. Total cancer incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  6. All-cause mortality rate

    National death registry, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  7. CVD-mortality rate,

    National death registry, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  8. Cancer-mortality rate

    National death registry, self-reported or medication check

    Measured: Minimum of five years of median follow-up

Secondary outcomes (4)
  1. Total dementia incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  2. Undefined dementia incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  3. Alzheimer's disease incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

  4. Parkinson's disease incidence

    Medical diagnosis, self-reported or medication check

    Measured: Minimum of five years of median follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Oct 2025
  2. Study start1 Oct 2025
  3. Primary completion30 Jun 2026 (estimated)
  4. Study completion30 Jan 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07205978
Sponsor's protocol ID
NUTPOOL
Acronym
NUTPOOL
Status last verified
Mar 2026
First submitted
26 Sep 2025
Last updated
20 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual cohorts only send summary data as per the harmonised analysis plan to the study leads. Therefore, the individual participant data remain with the individual cohorts.

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes (DM) and Cardio Vascular Disease, run by Institut Investigacio Sanitaria Pere Virgili at 2 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Denmark, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Type-2 diabetes incidence (time frame: Minimum of five years of median follow-up). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in